Novo Nordisk is capturing significant attention as investors weigh the potential of its oral Wegovy pill against Eli Lilly's recent market entry, with the company's new AI partnership with OpenAI further fueling hopes for accelerated drug discovery. Despite recent share price volatility, the community is actively debating the stock's valuation, dividend yield, and the long-term impact of evolving GLP-1 competitive dynamics.
Want to see this trending summary?